Kandesartan w badaniach klinicznych Omówienie
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2013
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Siński , M. (2013). Kandesartan w badaniach klinicznych . Medycyna Faktów , 6(2(19), 85-89. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2420
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Cuspidi C., Muiesan M.L., Valagussa L., Salvetti M., Di Biagio C., Agabiti-Rosei E., Magnani B., Zanchetti A.; CATCH investigators: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. Hypertens. 2002; 20(11): 2293-300.
2. Barrios V., Escobar C., Calderón A., Tomás J.P., Ruiz S., Moya J.L., Megías A., Vegazo O., Fernandez R.: Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J. Renin Angiotensin Aldosterone Syst. 2006; 7(4): 236-42.
3. de Simone G., Gottdiener J.S., Chinali M., Maurer M.S.: Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur. Heart J. 2008; 29(6): 741-7.
2. Barrios V., Escobar C., Calderón A., Tomás J.P., Ruiz S., Moya J.L., Megías A., Vegazo O., Fernandez R.: Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J. Renin Angiotensin Aldosterone Syst. 2006; 7(4): 236-42.
3. de Simone G., Gottdiener J.S., Chinali M., Maurer M.S.: Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur. Heart J. 2008; 29(6): 741-7.